GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the Fourth Quarter of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness.

In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to destroy solid tumors by the local generation of a potent cytotoxic agent within treated tumors while also enhancing immune checkpoint inhibitor activity against both treated and untreated tumors. Gedeptin has completed a multicenter Phase 1/2 clinical trial evaluating its use as monotherapy in advanced head and neck cancer. Combination strategies, including neoadjuvant and first-line settings of Gedeptin, in combination with other cancer treatment modalities, are being evaluated. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities.

At GeoVax, we are guided by the following strategic imperatives as we develop and grow our Company:

• Innovate – Pursuing the development of unique, patented products addressing unmet medical needs

• Differentiate – Targeting populations underserved by existing products/standard of care

• Accelerate – Focused on expedited registration pathways

• Collaborate – Achieve worldwide distribution via business collaborations